• HCW Biologics plans a first-in-human cancer study of HCW11-018b in the first half of 2027, following FDA guidance on its IND application.
• Preclinical findings will be presented November 6, 2026, at the Society for Immunotherapy of Cancer annual meeting in Phoenix.
• The candidate promoted immune-cell infiltration and immune structure formation within tumors, supporting its potential use against solid tumors.
• Tumor models showed reduced growth and metastatic spread, with complete shrinkage of patient-derived pancreatic tumor implants in some models.
• Manufacturing under current good manufacturing practices has begun to support potential clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060915PRIMZONEFULLFEED9871919) on November 06, 2026, and is solely responsible for the information contained therein.